FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
Resources >

Life Sciences Industry Acronyms >

Generics & Biosimilars Industry Acronyms

Generics & Biosimilars Industry Acronyms

Receive consulting resources in your inbox

This glossary defines regulatory, scientific, quality, market-access, and lifecycle terminology used across the Life Sciences sector, with emphasis on the Generics & Biosimilars Practice. It helps executives and practitioners interpret filings, equivalence evidence, analytical comparability, manufacturing controls, pharmacovigilance, pricing, and competition.

A B C D E F G H I J K L M N O P Q R S T U V W X

A
AAM Association for Accessible Medicines:
A United States trade association representing generic and biosimilar medicine manufacturers on policy, competition, supply, and patient-access issues.
ABE Average Bioequivalence:
The standard statistical approach for comparing average exposure measures between test and reference products, typically using confidence intervals for pharmacokinetic ratios.
ADA Anti-Drug Antibody:
An immune response directed against a therapeutic biologic. Its incidence, titer, neutralizing potential, and clinical consequences are evaluated when comparing a biosimilar with its reference product.
ADCC Antibody-Dependent Cellular Cytotoxicity:
An Fc-mediated mechanism through which immune cells kill antibody-bound target cells. Comparative functional testing may be critical when this activity contributes to a biologic’s clinical effect.
ADR Adverse Drug Reaction:
A harmful and unintended response for which a causal relationship to a medicine is at least reasonably possible. Monitoring supports product safety evaluation and regulatory reporting.
AE Adverse Event:
Any unfavorable medical occurrence associated with use of a medicine, whether or not considered causally related. Comparative safety and immunogenicity studies systematically collect and assess these events.
AEX Anion-Exchange Chromatography:
A charge-based analytical or purification method used to separate protein variants. It is frequently applied to compare biosimilar and reference-product charge profiles.
ANDA Abbreviated New Drug Application:
The United States application used to seek approval of a generic drug by demonstrating pharmaceutical equivalence, bioequivalence, appropriate manufacturing controls, and compliant labeling.
ANOVA Analysis of Variance:
A statistical method used in bioequivalence studies to estimate treatment, sequence, period, subject, and other sources of variability.
ANVISA Agência Nacional de Vigilância Sanitária:
Brazil’s national health regulatory authority, responsible for reviewing medicines, inspecting manufacturing operations, and establishing requirements for generic and biosimilar products.
API Active Pharmaceutical Ingredient:
The substance responsible for a medicine’s pharmacological activity. Its identity, quality, source, specifications, and supply reliability are central to generic product approval and continuity.
APR Annual Product Review:
A periodic evaluation of manufacturing and quality data used to identify trends, verify process consistency, and determine whether corrective or preventive action is needed.
ASMF Active Substance Master File:
A European regulatory dossier that allows an active-substance manufacturer to protect confidential process information while giving authorities sufficient data to assess substance quality.
ASP Average Sales Price:
A United States reimbursement benchmark based on manufacturer-reported sales data. It is especially important for physician-administered biosimilars reimbursed under Medicare Part B.
ATC Anatomical Therapeutic Chemical Classification System:
A World Health Organization system that classifies medicines by target organ or system and therapeutic, pharmacological, and chemical characteristics, supporting market and utilization analysis.
AUC Area Under the Concentration–Time Curve:
A pharmacokinetic measure of total systemic drug exposure. Ratios of test and reference values are primary endpoints in many bioequivalence assessments.
AWP Average Wholesale Price:
A published pharmaceutical pricing benchmark used in some reimbursement and contracting contexts, although it does not necessarily represent actual transaction prices.
B
BA Bioavailability:
The rate and extent at which an active ingredient becomes available at its site of action, commonly assessed through systemic exposure measurements.
BAN British Approved Name:
The official nonproprietary name assigned to a medicinal substance in the United Kingdom, generally aligned with international naming conventions.
BCS Biopharmaceutics Classification System:
A framework that categorizes drug substances by aqueous solubility and intestinal permeability. It can support waivers of in vivo bioequivalence studies when specified criteria are met.
BE Bioequivalence:
The absence of a meaningful difference in the rate and extent of active-ingredient availability between test and reference products under comparable conditions.
BLA Biologics License Application:
The United States application for authorization to market a biological product. Biosimilars and interchangeable biosimilars are submitted through the abbreviated pathway established for biological products.
BLQ Below the Limit of Quantification:
A designation for bioanalytical results beneath the lowest concentration that can be measured with validated accuracy and precision.
BMV Bioanalytical Method Validation:
The documented demonstration that an assay reliably measures drug, metabolite, or biomarker concentrations for pharmacokinetic, bioequivalence, or comparative studies.
BP British Pharmacopoeia:
The United Kingdom’s official compendium of medicinal-substance and product quality standards, including monographs and analytical methods relevant to generic medicines.
BPCIA Biologics Price Competition and Innovation Act:
The United States law that created the abbreviated licensure pathway for biosimilar and interchangeable biological products and established associated exclusivity and patent procedures.
BSE Bovine Spongiform Encephalopathy:
A transmissible neurological disease relevant to the viral and adventitious-agent safety assessment of biologically sourced materials used in pharmaceutical manufacturing.
C
CAPA Corrective and Preventive Action:
A quality-system process for investigating problems, correcting root causes, preventing recurrence, and verifying the effectiveness of resulting actions.
CBE-0 Changes Being Effected—0 Days:
A United States post-approval supplement category that can permit distribution of a product with certain changes upon the regulator’s receipt of the submission.
CBE-30 Changes Being Effected—30 Days:
A United States post-approval supplement category under which qualifying changes generally may be implemented 30 days after the regulator receives the submission.
CBER Center for Biologics Evaluation and Research:
The United States Food and Drug Administration center responsible for regulating specified biological products, including many products serving as references for biosimilar development.
CDER Center for Drug Evaluation and Research:
The United States Food and Drug Administration center that reviews generic drugs and many therapeutic biological products, including biosimilars.
CDSCO Central Drugs Standard Control Organisation:
India’s national regulatory body for medicines, responsible for central approvals, standards, clinical-trial oversight, and coordination with state regulators.
CEP Certificate of Suitability to the Monographs of the European Pharmacopoeia:
A certificate demonstrating that relevant pharmacopoeial monographs adequately control the quality of a substance produced by a specified manufacturer and process.
CE-SDS Capillary Electrophoresis–Sodium Dodecyl Sulfate:
An analytical method used to assess protein size variants, purity, fragments, and aggregates under reducing or nonreducing conditions.
CGT Competitive Generic Therapy:
A United States designation for a generic version of a drug with inadequate generic competition. It can provide expedited review and eligibility for a limited exclusivity period.
CHMP Committee for Medicinal Products for Human Use:
The European Medicines Agency committee that prepares scientific opinions on human medicines, including centrally reviewed biosimilars.
CI Confidence Interval:
A statistical range expressing uncertainty around an estimated treatment ratio or difference. Prespecified intervals are central to bioequivalence and comparative clinical analyses.
cIEF Capillary Isoelectric Focusing:
A high-resolution method that separates protein charge variants according to isoelectric point, supporting comparative characterization of biological products.
CMA Critical Material Attribute:
A physical, chemical, biological, or microbiological property of an input material that must be controlled to assure desired product quality.
Cmax Maximum Observed Plasma Concentration:
The highest measured drug concentration after dosing and a primary indicator of absorption rate in many bioequivalence studies.
CMC Chemistry, Manufacturing, and Controls:
The regulatory information describing product composition, manufacturing processes, facilities, analytical methods, specifications, stability, and quality controls.
CMDh Coordination Group for Mutual Recognition and Decentralised Procedures—Human:
The European body that addresses questions and disagreements arising from national, mutual-recognition, and decentralized authorization procedures for human medicines.
CMS Centers for Medicare & Medicaid Services:
The United States agency administering major public health-insurance programs and establishing reimbursement policies that materially affect biosimilar adoption and pricing.
CMS Concerned Member State:
An EU or European Economic Area country participating in a decentralized or mutual-recognition procedure while relying on the lead assessment conducted by the reference member state.
CoA Certificate of Analysis:
A controlled document reporting batch-specific test results and confirming whether a material or product meets approved specifications.
CPP Certificate of Pharmaceutical Product:
A World Health Organization-format document issued by a national authority to communicate a medicine’s authorization and manufacturing status for international registration or procurement.
CPP Critical Process Parameter:
A process variable whose variability can affect a critical quality attribute and therefore requires monitoring or control.
CPV Continued Process Verification:
Ongoing collection and analysis of manufacturing data to confirm that a commercial process remains in a validated state of control.
CQA Critical Quality Attribute:
A physical, chemical, biological, or microbiological property that must remain within appropriate limits to ensure product quality, safety, and efficacy.
CRL Complete Response Letter:
A United States regulatory communication stating that an application cannot be approved in its current form and identifying deficiencies requiring resolution.
CTD Common Technical Document:
The internationally harmonized structure used to organize quality, nonclinical, and clinical information in medicine applications.
CVw Within-Subject Coefficient of Variation:
A measure of how much a pharmacokinetic parameter varies within the same individual, used in study design and reference-scaled bioequivalence calculations.
D
DCGI Drugs Controller General of India:
The official heading India’s central drug regulatory functions, including specified approvals, clinical-trial oversight, and national standards implementation.
DCP Decentralised Procedure:
A European authorization route through which an applicant seeks simultaneous approval in multiple countries when the medicine has not already been authorized in the region.
DDD Defined Daily Dose:
The assumed average maintenance dose per day for a medicine’s principal adult indication, used to standardize utilization and market comparisons.
DDI Drug–Drug Interaction:
A change in a medicine’s exposure or effect caused by another medicine. Established interaction information generally informs generic labeling and study requirements.
DIN Drug Identification Number:
The unique eight-digit identifier assigned by Health Canada to an authorized drug product, strength, dosage form, and manufacturer.
DLS Dynamic Light Scattering:
An analytical technique used to estimate particle size distributions and detect aggregation in protein formulations and other dispersed systems.
DMF Drug Master File:
A confidential regulatory submission containing information about facilities, processes, or materials that can be referenced by one or more medicine applications.
DP Drug Product:
The finished dosage form containing the active substance and excipients, presented in the packaging intended for administration or distribution.
DPI Dry Powder Inhaler:
A device that delivers an inhaled medicine as a dry powder. Generic development requires comparative evaluation of formulation, device performance, deposition, and user interaction.
DS Drug Substance:
The active material that is formulated into the finished product, including a purified biological active ingredient before final formulation and filling.
DSC Differential Scanning Calorimetry:
A thermal analysis method used to characterize protein stability, conformational transitions, polymorphs, and formulation behavior.
DVS Dynamic Vapor Sorption:
A technique that measures moisture uptake and release under controlled humidity, helping characterize active ingredients, excipients, and dosage-form stability.
E
EC European Commission:
The EU institution that grants legally binding centralized marketing authorizations after receiving a scientific opinion from the European Medicines Agency.
eCTD Electronic Common Technical Document:
The standardized electronic format and lifecycle structure used to submit and maintain medicine applications across major regulatory jurisdictions.
EDQM European Directorate for the Quality of Medicines & HealthCare:
The Council of Europe directorate responsible for the European Pharmacopoeia, substance-suitability certification, and other medicine-quality programs.
EEA European Economic Area:
The common market comprising the European Union member states plus Iceland, Liechtenstein, and Norway, within which coordinated medicine procedures operate.
EMA European Medicines Agency:
The EU agency coordinating scientific evaluation, supervision, and safety monitoring of medicines, including centralized biosimilar applications.
EP European Pharmacopoeia:
The legally recognized European compendium of quality standards for medicinal substances, dosage forms, analytical methods, and specified biological products.
EPAR European Public Assessment Report:
A public record explaining the European Medicines Agency’s scientific assessment and the basis for the authorization or refusal of a centrally reviewed medicine.
ER Extended Release:
A dosage-form design that releases active ingredient over a prolonged period. Generic versions require suitable comparative dissolution and bioequivalence evidence.
ERP Expert Review Panel:
An independent review mechanism used in global health procurement to assess the quality risks of certain medicines not yet approved by a recognized authority or prequalified by the World Health Organization.
F
f2 Similarity Factor:
A logarithmic metric used to compare two dissolution profiles. Values meeting applicable regulatory criteria can support a conclusion that the profiles are similar.
Fc Fragment Crystallizable Region:
The antibody region that interacts with immune receptors and complement proteins. Its structure, glycosylation, binding, and effector functions are important in many biosimilar comparisons.
FcRn Neonatal Fc Receptor:
A receptor involved in recycling immunoglobulin G and influencing antibody half-life. Comparative binding can be relevant to biosimilar pharmacokinetic similarity.
FDA Food and Drug Administration:
The United States agency responsible for reviewing, approving, inspecting, and monitoring generic drugs and biosimilar biological products.
FDC Fixed-Dose Combination:
A single dosage form containing two or more active ingredients in fixed proportions. Generic development must address equivalence and product performance for each component.
FD&C Act Federal Food, Drug, and Cosmetic Act:
The principal United States statute governing drugs, including the legal framework under which abbreviated generic drug applications are reviewed.
FDF Finished Dosage Form:
The completed pharmaceutical form, such as a tablet, injection, or inhalation product, containing the active ingredient and ready for packaging or use.
FPP Finished Pharmaceutical Product:
A medicine that has completed all production stages, including final packaging, and is ready for distribution or procurement.
FTIR Fourier-Transform Infrared Spectroscopy:
An analytical technique used to identify materials and compare molecular structure, secondary structure, solid-state properties, or formulation components.
G
G-BA Gemeinsamer Bundesausschuss:
Germany’s Federal Joint Committee, which sets binding healthcare coverage and prescribing rules that can influence biosimilar use, substitution, and reimbursement.
GCP Good Clinical Practice:
The ethical and scientific quality standard governing the design, conduct, recording, and reporting of clinical and bioequivalence studies involving human participants.
GDUFA Generic Drug User Fee Amendments:
The United States program through which industry fees fund generic drug reviews and inspections under defined performance goals and commitments.
GLP Good Laboratory Practice:
A quality framework for the organization, conduct, documentation, and reporting of specified nonclinical laboratory studies submitted to regulators.
GMP Good Manufacturing Practice:
The regulatory requirements ensuring that medicines are consistently produced and controlled to approved quality standards.
GMR Geometric Mean Ratio:
The ratio of log-transformed pharmacokinetic averages for test and reference products, commonly used with a confidence interval to assess bioequivalence.
H
HCP Host Cell Protein:
A process-related impurity originating from cells used to manufacture a biological product. Residual profiles and levels are closely controlled and compared during biosimilar development.
HCPCS Healthcare Common Procedure Coding System:
The United States coding system used to bill healthcare services and physician-administered medicines. Product-specific or shared codes can affect biosimilar reimbursement and uptake.
HHS Department of Health and Human Services:
The United States cabinet department overseeing federal health agencies and policies affecting medicine regulation, reimbursement, competition, and supply.
HILIC Hydrophilic Interaction Liquid Chromatography:
A chromatographic technique used to separate highly polar compounds and characterize glycan profiles in comparative biological-product analysis.
HMA Heads of Medicines Agencies:
A network of European national regulatory authorities that coordinates medicine regulation and supports mutual-recognition and decentralized procedures.
HOS Higher-Order Structure:
The three-dimensional folding and assembly of a biological molecule. Orthogonal methods are used to compare this structure because it can affect function, stability, and immunogenicity.
HPLC High-Performance Liquid Chromatography:
A widely used analytical platform for measuring identity, assay, purity, impurities, degradation products, and release characteristics.
HVD Highly Variable Drug:
A drug for which a pharmacokinetic measure shows high within-subject variability. Replicate study designs and reference-scaled approaches may be appropriate under applicable guidance.
I
ICH International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use:
The global body that develops harmonized guidelines covering quality, safety, efficacy, and multidisciplinary regulatory topics.
icIEF Imaged Capillary Isoelectric Focusing:
A whole-column imaging method used to quantify protein charge variants and compare isoelectric-point distributions.
ICSR Individual Case Safety Report:
A structured report describing one or more suspected adverse reactions in an individual patient, submitted and exchanged through pharmacovigilance systems.
IGBA International Generic and Biosimilar Medicines Association:
A global industry association representing manufacturers and national associations on regulatory convergence, access, competition, and sustainable supply.
INN International Nonproprietary Name:
The World Health Organization-designated public name for a pharmaceutical substance, enabling consistent identification across countries and brands.
IP Intellectual Property:
Patents, regulatory exclusivities, trade secrets, trademarks, and related rights that influence development timing, launch strategy, and competitive entry.
IPC In-Process Control:
A test or check performed during manufacturing to monitor the process and, when necessary, adjust it before the finished product is released.
IPR Inter Partes Review:
A United States Patent and Trademark Office proceeding used to challenge patentability, often considered in generic and biosimilar patent strategies.
IPRP International Pharmaceutical Regulators Programme:
A forum for regulatory authorities to exchange information and promote convergence in pharmaceutical regulation, including generic and biosimilar oversight.
IR Immediate Release:
A dosage form designed to release active ingredient without deliberate delay or prolonged delivery. Comparative dissolution and exposure are central to generic development.
ISR Incurred Sample Reanalysis:
Repeat analysis of selected study samples used to verify that a validated bioanalytical method performs reproducibly with real subject specimens.
IVIVC In Vitro–In Vivo Correlation:
A predictive relationship between an in vitro product characteristic, usually dissolution or release, and an in vivo response such as drug exposure.
IVPT In Vitro Permeation Test:
A laboratory method that measures drug permeation through excised skin or another membrane, frequently used in developing generic topical products.
IVRT In Vitro Release Test:
A method that measures the rate and extent of drug release from semisolid or other locally acting dosage forms under controlled laboratory conditions.
J
JP Japanese Pharmacopoeia:
Japan’s official compendium of standards for medicinal substances, dosage forms, testing methods, and product quality.
K
KASA Knowledge-aided Assessment and Structured Application:
A United States Food and Drug Administration system for structured generic-drug quality assessment, risk identification, knowledge management, and lifecycle review.
L
LC–MS/MS Liquid Chromatography–Tandem Mass Spectrometry:
A sensitive analytical platform widely used to quantify drugs and metabolites in biological samples for pharmacokinetic and bioequivalence studies.
LDD Locally Acting Drug Product:
A medicine intended to act primarily at its administration site, such as a topical, inhaled, ophthalmic, or gastrointestinal product. Equivalence may require specialized in vitro, pharmacodynamic, or clinical evidence.
LLOQ Lower Limit of Quantification:
The lowest analyte concentration that a validated assay can quantify with acceptable accuracy and precision.
LOE Loss of Exclusivity:
The point at which patent or regulatory protections cease to block follow-on competition, often triggering generic or biosimilar launches and rapid market change.
LSM Least-Squares Mean:
A model-adjusted mean used in statistical analyses of log-transformed pharmacokinetic endpoints and other comparative study measures.
M
MA Marketing Authorisation:
The regulatory approval permitting a specified medicinal product to be placed on the market in a jurisdiction.
MAA Marketing Authorisation Application:
The dossier submitted to a regulator seeking permission to market a medicinal product, including generic and biosimilar applications.
MAC Maximum Allowable Cost:
A payer or pharmacy-benefit reimbursement ceiling commonly applied to groups of therapeutically equivalent multisource medicines.
MAH Marketing Authorisation Holder:
The legal entity responsible for an authorized medicine, including its quality, safety monitoring, regulatory maintenance, and supply obligations.
MALS Multi-Angle Light Scattering:
An analytical technique used to determine absolute molecular mass and characterize aggregates or other size variants in biological products.
MBR Master Batch Record:
The approved manufacturing instructions and controls used to produce and document each batch of a medicinal product.
MDI Metered-Dose Inhaler:
A device that delivers a measured quantity of aerosolized medicine. Generic equivalence requires coordinated evaluation of formulation, device, emitted dose, particle size, and use technique.
MedDRA Medical Dictionary for Regulatory Activities:
The standardized international terminology used to code adverse events, indications, medical history, and other regulatory safety information.
MFDS Ministry of Food and Drug Safety:
South Korea’s national regulatory authority for medicines, responsible for product approval, quality oversight, inspections, and post-market safety.
MHLW Ministry of Health, Labour and Welfare:
The Japanese ministry responsible for national health policy and the legal and administrative framework governing medicinal products.
MHRA Medicines and Healthcare products Regulatory Agency:
The United Kingdom authority responsible for regulating medicines, including generic and biosimilar approvals, inspections, and safety monitoring.
MoA Mechanism of Action:
The biological process through which a medicine produces its effect. Understanding all clinically relevant mechanisms guides biosimilar functional testing and indication extrapolation.
MR Modified Release:
A dosage form engineered to alter the timing, rate, or location of active-ingredient release compared with an immediate-release product.
MRP Mutual Recognition Procedure:
A European route through which countries recognize an existing national marketing authorization based on assessment by a reference member state.
MS Mass Spectrometry:
An analytical technique used to identify and quantify molecules and characterize sequence, modifications, impurities, metabolites, and structural attributes.
N
NADAC National Average Drug Acquisition Cost:
A United States survey-based benchmark estimating pharmacy acquisition costs for outpatient drugs, including multisource generic products.
NDA New Drug Application:
The United States application for approval of a new drug. An approved product may subsequently become the reference for an abbreviated generic application.
NDC National Drug Code:
A United States product identifier that specifies the labeler, product, and package configuration for a marketed drug.
NICE National Institute for Health and Care Excellence:
The United Kingdom body that develops evidence-based guidance affecting medicine use, commissioning, and biosimilar adoption in England and Wales.
NMPA National Medical Products Administration:
China’s national regulator for medicines and medical products, responsible for registration, manufacturing oversight, inspections, and post-market supervision.
NMR Nuclear Magnetic Resonance:
A spectroscopic technique used to characterize molecular structure, composition, conformation, and interactions in active ingredients and biological products.
NOC Notice of Compliance:
Health Canada’s formal notification that a medicine meets applicable requirements and is authorized for sale, subject to stated conditions.
NTI Narrow Therapeutic Index:
A designation for drugs where small exposure differences may cause therapeutic failure or serious toxicity, often leading to tighter bioequivalence expectations.
O
ODT Orally Disintegrating Tablet:
A tablet designed to disintegrate rapidly in the mouth. Generic development must address disintegration, palatability, dissolution, and bioequivalence.
OGD Office of Generic Drugs:
The office within the United States Food and Drug Administration responsible for reviewing abbreviated generic applications and developing related regulatory science and guidance.
OINDP Orally Inhaled and Nasal Drug Products:
A category of locally acting drug-device combination products that often requires specialized evidence of formulation, device, aerosol, deposition, pharmacokinetic, or clinical equivalence.
OOS Out of Specification:
A test result falling outside an approved specification or acceptance criterion and requiring a scientifically sound investigation.
OOT Out of Trend:
A result that remains within specification but differs unexpectedly from historical or anticipated patterns and may warrant investigation.
OSD Oral Solid Dosage:
A category including tablets, capsules, and related products, representing a major portion of conventional generic medicine development and manufacturing.
P
PACMP Post-Approval Change Management Protocol:
A regulatory tool describing how a future change will be developed, validated, assessed, and reported, enabling more predictable product lifecycle management.
PADER Periodic Adverse Drug Experience Report:
A United States post-market safety report summarizing specified adverse-experience information for an approved product over a defined period.
PAS Prior Approval Supplement:
A United States submission for a major post-approval change that generally requires regulatory approval before implementation.
PAT Process Analytical Technology:
A framework for designing, analyzing, and controlling manufacturing through timely measurement of critical material and process attributes.
pAUC Partial Area Under the Concentration–Time Curve:
Drug exposure measured over a specified portion of the concentration-time profile, used when total exposure alone does not adequately distinguish formulation performance.
PBE Population Bioequivalence:
A statistical approach comparing both mean performance and variability between test and reference products, used in selected product-specific equivalence frameworks.
PBM Pharmacy Benefit Manager:
An organization that administers prescription-drug benefits, negotiates rebates and network terms, and manages formularies and reimbursement affecting generic and biosimilar access.
PBRER Periodic Benefit-Risk Evaluation Report:
A harmonized pharmacovigilance report providing an integrated periodic evaluation of new safety information and the medicine’s overall benefit-risk profile.
PD Pharmacodynamics:
The study of a medicine’s biological and physiological effects. Sensitive biomarkers can provide comparative evidence when pharmacokinetic data alone are insufficient.
PIL Patient Information Leaflet:
The patient-facing document explaining how to use a medicine, its risks, precautions, and other essential information.
PIV Paragraph IV Certification:
A certification in a United States generic application asserting that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product.
PK Pharmacokinetics:
The study of drug absorption, distribution, metabolism, and elimination. Comparative exposure measurements form the basis of many generic and biosimilar studies.
PK/PD Pharmacokinetics/Pharmacodynamics:
The integrated relationship between drug exposure and biological response, used to select sensitive doses, populations, endpoints, and equivalence margins.
PL Package Leaflet:
The EU-required document supplied to patients with a medicine and derived from the approved product information.
PMDA Pharmaceuticals and Medical Devices Agency:
Japan’s regulatory agency for scientific review, consultations, inspections, and safety measures involving medicinal products.
pMDI Pressurized Metered-Dose Inhaler:
An inhaler that uses a pressurized propellant to deliver a measured aerosol dose. Generic comparability depends on both formulation and device performance.
PPQ Process Performance Qualification:
The documented demonstration that a commercial manufacturing process can reproducibly produce product meeting predefined quality requirements.
PQP Prequalification Programme:
The World Health Organization program that assesses medicines, manufacturing sites, and quality-control laboratories to support procurement by international agencies and countries.
PQR Product Quality Review:
A periodic evaluation of batches, deviations, changes, stability, complaints, and process performance used to confirm consistency and identify improvement opportunities.
PRAC Pharmacovigilance Risk Assessment Committee:
The European Medicines Agency committee responsible for assessing and monitoring safety issues for human medicines.
PSD Particle Size Distribution:
The range and relative proportion of particle sizes in a material or formulation, which can influence dissolution, aerosol performance, stability, and local delivery.
PSG Product-Specific Guidance:
United States Food and Drug Administration recommendations describing appropriate studies and methods for demonstrating equivalence for a particular reference drug.
PSMF Pharmacovigilance System Master File:
A detailed description of the pharmacovigilance system operated by a marketing authorization holder, maintained for regulatory oversight and inspection.
PSUR Periodic Safety Update Report:
A recurring post-market report summarizing worldwide safety data and evaluating whether new information affects a medicine’s benefit-risk balance.
PTAB Patent Trial and Appeal Board:
The United States administrative tribunal that hears patentability challenges, including proceedings relevant to generic and biosimilar market entry.
PV Pharmacovigilance:
The science and activities concerned with detecting, assessing, understanding, and preventing adverse effects and other medicine-related safety problems.
Q
Q1 Qualitative Sameness:
A formulation comparison showing that the test and reference products contain the same inactive ingredients, subject to applicable regulatory interpretation.
Q2 Quantitative Sameness:
A formulation comparison showing that corresponding inactive ingredients are present in the same concentrations or amounts within applicable tolerances.
Q3 Structural and Physicochemical Sameness:
Comparative characterization of properties beyond ingredient identity and quantity, such as microstructure, particle size, rheology, release behavior, or arrangement within the formulation.
QbD Quality by Design:
A systematic development approach that begins with predefined objectives and uses product, process, and risk understanding to establish robust controls.
QMS Quality Management System:
The integrated governance, processes, responsibilities, procedures, and resources used to ensure consistent regulatory and product-quality compliance.
QP Qualified Person:
The legally designated professional in European pharmaceutical manufacturing who certifies that each batch complies with authorization and good-manufacturing requirements before release.
QPPV Qualified Person Responsible for Pharmacovigilance:
The individual with defined legal responsibility for establishing and maintaining a compliant pharmacovigilance system in the European regulatory framework.
R
REMS Risk Evaluation and Mitigation Strategy:
A United States safety program required for certain medicines when additional measures beyond standard labeling are needed to ensure benefits outweigh risks.
RLD Reference Listed Drug:
The approved United States drug identified as the product against which a proposed generic must demonstrate pharmaceutical equivalence and bioequivalence.
RMP Reference Medicinal Product:
The authorized medicine used as the comparator for generic or biosimilar development in European and other regulatory frameworks.
RMP Risk Management Plan:
A regulatory document describing a medicine’s safety profile, pharmacovigilance activities, and measures for preventing or minimizing identified and potential risks.
RMS Reference Member State:
The European country leading the scientific assessment in a decentralized or mutual-recognition authorization procedure.
RP Reference Product:
The previously authorized biological product against which a proposed biosimilar is compared to establish biosimilarity.
RP-HPLC Reversed-Phase High-Performance Liquid Chromatography:
A separation technique used to assess identity, purity, hydrophobic variants, degradation products, and peptide profiles.
RS Reference Standard:
In the United States generic framework, the approved product selected for use in required in vivo bioequivalence studies when it may differ from the listed reference product.
RSABE Reference-Scaled Average Bioequivalence:
A statistical method that scales bioequivalence limits according to within-subject variability of the reference product, subject to regulatory constraints.
RTR Refuse-to-Receive:
A United States generic-drug filing outcome indicating that an application is not sufficiently complete for substantive review.
S
SABE Scaled Average Bioequivalence:
An equivalence approach that adjusts acceptance limits based on variability, used under defined regulatory conditions for selected highly variable measures or products.
SAHPRA South African Health Products Regulatory Authority:
South Africa’s regulator for medicines and health products, responsible for registration, licensing, inspections, and post-market oversight.
SAWP Scientific Advice Working Party:
The European Medicines Agency group supporting scientific advice on development plans, studies, endpoints, and evidence requirements.
SBP Similar Biotherapeutic Product:
The World Health Organization term for a biological product shown to be similar in quality, safety, and efficacy to an already licensed reference biotherapeutic product.
SC Subcutaneous:
A route of administration in which a medicine is injected beneath the skin. Formulation, device, immunogenicity, and absorption can be important in biosimilar comparisons.
SEB Subsequent Entry Biologic:
A legacy Canadian term for a biologic developed with reference to an already authorized biological product; current Canadian terminology generally uses biosimilar biologic drug.
SEC Size-Exclusion Chromatography:
A method that separates molecules by hydrodynamic size and is widely used to quantify aggregates, fragments, and monomer content in biological products.
SmPC Summary of Product Characteristics:
The approved European document describing a medicine’s indications, dosing, contraindications, warnings, pharmacology, and other information for healthcare professionals.
SOP Standard Operating Procedure:
An approved written instruction designed to ensure that recurring regulated activities are performed consistently and traceably.
SPC Supplementary Protection Certificate:
A European intellectual-property right that can extend protection for an authorized medicinal product beyond the underlying patent term, affecting market-entry timing.
SPR Surface Plasmon Resonance:
A label-free technique for measuring molecular binding affinity and kinetics, frequently used to compare biosimilar and reference-product receptor or ligand interactions.
SRA Stringent Regulatory Authority:
A legacy World Health Organization concept for authorities applying recognized regulatory standards, historically used in global procurement and reliance decisions.
SUPAC Scale-Up and Post-Approval Changes:
United States guidance frameworks addressing documentation, testing, and filing expectations for specified manufacturing, composition, site, and scale changes.
T
TE Therapeutic Equivalence:
A United States designation indicating that approved pharmaceutical equivalents are expected to have the same clinical effect and safety profile when used as labeled.
TGA Therapeutic Goods Administration:
Australia’s national regulator for medicines and therapeutic goods, responsible for market authorization, manufacturing oversight, and safety monitoring.
Tmax Time to Maximum Plasma Concentration:
The elapsed time from dosing to the highest observed drug concentration, used as a descriptive measure of absorption rate.
TSE Transmissible Spongiform Encephalopathy:
A class of prion diseases relevant to risk assessments and controls for animal-derived materials used in pharmaceutical and biological manufacturing.
U
UHPLC Ultra-High-Performance Liquid Chromatography:
A high-pressure chromatographic technique offering rapid, high-resolution separation for assay, impurity, stability, and structural-characterization testing.
ULOQ Upper Limit of Quantification:
The highest analyte concentration that a validated method can quantify with acceptable accuracy and precision without additional dilution or qualification.
UPLC Ultra Performance Liquid Chromatography:
A high-resolution liquid-chromatography platform used for rapid analysis of active ingredients, impurities, peptides, glycans, and protein variants.
USAN United States Adopted Name:
The official nonproprietary name assigned to a drug substance for use in the United States, generally coordinated with international naming conventions.
USP United States Pharmacopeia:
The official United States compendium establishing public standards for medicine identity, strength, quality, purity, packaging, and testing.
V
VAI Voluntary Action Indicated:
A United States Food and Drug Administration inspection classification indicating objectionable conditions that do not currently warrant regulatory enforcement action but should be corrected.
W
WAC Wholesale Acquisition Cost:
A United States manufacturer-reported list-price benchmark excluding most discounts and rebates, used in contracting, reimbursement, and price comparisons.
WHO World Health Organization:
The United Nations health agency that develops medicine-quality, biosimilar, naming, procurement, and prequalification standards used internationally.
WHO PQ World Health Organization Prequalification:
An assessment process evaluating the quality, safety, and efficacy of priority medicines and the compliance of associated manufacturing sites for global procurement.
WLA WHO Listed Authority:
A regulatory authority or regional system documented by the World Health Organization as meeting specified performance indicators and operating at an advanced maturity level.
X
XRPD X-Ray Powder Diffraction:
An analytical technique used to identify and compare crystalline forms, polymorphs, salts, and degrees of crystallinity in active ingredients and formulations.